Reduced Sox7 Expression in Prostate Cancer and Associated with Poorly Differentiated Gleason Grade


  • Paul Whitley Department of Biology and Biochemistry, University of Bath, United Kingdom
  • Dhafer A. Alghezi Medical Microbiology and Immunology Department, Cancer Research Unit, College of Medicine, University of Thi-Qar, Iraq
  • Mark Beresford Department of Oncology, Royal United Hospital, Bath, United Kingdom
  • Rebecca Bowen and John Mitchard Department of Cellular Pathology, Royal United Hospital, Bath, United Kingdom
  • Andrew D Chalmers Department of Biology and Biochemistry, University of Bath, United Kingdom


Sox7, IHC, Gleason grade, Prostate cancer


Diagnostic and prognostic biomarkers for prostate cancer are few. It has been discovered that it is clinically challenging to discriminate between aggressive and non-aggressive prostate cancer. The aim of this study is to examine the hypothesis that Sox7 may be used as a potential biomarker for prostate cancer diagnosis and prognosis. Sox7 is a transcription factor that is found to play a role in controlling different biological processes throughout embryonic development, such as hemopoiesis, vasculogenesis, and cardiogenesis. It is also believed to be a tumor suppressor in a number of malignancies. Its function in prostate cancer, however, is not well understood. Nuclear and cytoplasmic Sox7 expression has been evaluated by immunohistochemistry using normal (16) and malignant (80) prostate tissues. The immunohistochemical study showed reduced nuclear and cytoplasmic Sox7 expression in prostate cancer compared to normal prostate tissues. This reduction was also associated significantly with increased primary Gleason grade.  This data suggests the possibility that Sox7 may play a key role in prostate tumor formation or aggressiveness, highlighting the need for further study to clarify its role and establish whether it might be used as a prognostic biomarker for prostate cancer.


Lang SH, Frame FM. and Collins AT. (2009) Prostate cancer stem cells. The Journal of pathology, 217(2), pp. 299-306.

Kirby RS. (2012) Prostate cancer. 7th ed. ed. Abingdon: Abingdon : Health Press.

Swami U, McFarland TR, Nussenzveig R, Agarwal N. (2020) Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer. 6(8):702-715. doi: 10.1016/j.trecan.2020.04.010. Epub 2020 Jun 10. PMID: 32534790.

Dunn MW and Kazer MW. (2011) Prostate Cancer Overview. Seminars in Oncology Nursing. 27(4), pp. 241-250.

Bagnall P. (2014) Diagnosis and treatment of prostate cancer. Nursing times. 110(9): p. 1215.

Stajno P, Kalinowski T, Ligaj M. and Demkow T. (2013) An incidentally diagnosed prostatic ductal adenocarcinoma. Cent European J Urol. 66(2):164-167. doi:10.5173/ceju.2013.

Gleason, D.F. (1966) Classification of prostatic carcinomas. Cancer Chemother. Rep. 50: p. 125-128.

Matoso, A. and Epstein, J.I. (2016) Grading of prostate cancer: past, present, and future. Current urology reports. 17(3): p. 1-6.

Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, (2013) Gleason grade progression is uncommon. Cancer research. 73(16), pp. 5163-8.

Edge SB and Compton CC. (2010)The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. 17(6): p. 1471-1474.

Goldstein AS, Huang J, Guo C, Garraway IP & Witte ON. (2010) Identification of a cell of origin for human prostate cancer. Science (New York, N.Y.). 329(5991), p. 568.

Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. (2002) Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 26(9):1161-8. doi: 10.1097/00000478-200209000-00006. PMID: 12218572.

Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PG. et al. (2002) Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Archives of pathology & laboratory medicine. 126(5), pp. 554-61.

Stovall, D.B., Cao, P. & Sui, G. (2014) SOX7: From a developmental regulator to an emerging tumor suppressor. Histology and Histopathology, 29(4), pp. 439-445.

Cui, J., Xi, H., Cai, A., Bian, S., Wei, B. & Chen, L. (2014) Decreased expression of Sox7 correlates with the upregulation of the Wnt/beta-catenin signaling pathway and the poor survival of gastric cancer patients. International journal of molecular medicine, 34(1), pp. 197204.

Liu, K.F. & Shan, Y.X. (2016) Effects of siRNA-mediated silencing of Sal-like 4 expression on proliferation and apoptosis of prostate cancer C4-2 cells. Genetics and molecular research : GMR, 15(2).

Liu, H., Yan, Z.Q., Li, B., Yin, S.Y., Sun, Q., Kou, J.J., Ye, D., Ferns, K., Liu, H.Y. & Liu, S.L. (2014) Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/beta-catenin signaling pathway. Journal of ovarian research, 7, p. 87.

Wang, F., Zhao, W., Kong, N., Cui, W. & Chai, L. (2014b)The next new target in leukemia: The embryonic stem cell gene. Molecular & cellular oncology, 1(4), p. e969169

Wang, J., Zhang, S., Wu, J., Lu, Z., Yang, J., Wu, H., Chen, H., Lin, B. & Cao, T. (2017) Clinical significance and prognostic value of SOX7 expression in liver and pancreatic carcinoma. Molecular medicine reports, 16(1), pp. 499-506.

Guo, L., Zhong, D., Lau, S., Liu, X., Dong, X.Y., Sun, X., Yang, V.W., Vertino, P.M., Moreno, C.S., Varma, V., Dong, J.T. & Zhou, W. (2008) Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Molecular cancer research : MCR, 6(9), pp. 1421-30.

Zhong, W.-d., Qin, G.-q., Dai, Q.-s., Han, Z.-d., Chen, S.-m., Ling, X.-h., Fu, X., Cai, C., Chen, J.-h., Chen, X.-b., Lin, Z.-y., Deng, Y.-h., Wu, S.-l., He, H.-c. & Wu, C.-l. (2012) SOXs in human prostate cancer: implication as progression and prognosis factors. Bmc Cancer,12.

Liu, H., Mastriani, E., Yan, Z.Q., Yin, S.Y., Zeng, Z., Wang, H., Li, Q.H., Liu, H.Y., Wang, X., Bao, H.X., Zhou, Y.J., Kou, J.J., Li, D., Li, T., Liu, J., Liu, Y., Yin, L., Qiu, L., Gong, L. & Liu, S.L. (2016) SOX7 co-regulates Wnt/beta-catenin signaling with Axin-2: both expressed at low levels in breast cancer. Scientific reports, 6, p. 26136.

Takash, W., Canizares, J., Bonneaud, N., Poulat, F., Mattei, M.G., Jay, P. & Berta, P. (2001) SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling. Nucleic acids research, 29(21), pp. 427483.

Chang, X., Zhang, S., Ma, J., Li, Z., Zhi, Y., Chen, J., Lu, Y. & Dai, D. (2013) Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens. Cell biochemistry and biophysics, 66(1), pp. 93-101.

Oba, K., Matsuyama, H., Yoshihiro, S., Kishi, F., Takahashi, M., Tsukamoto, M., Kinjo, M., Sagiyama, K. & Naito, K. (2001) Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer genetics and cytogenetics, 124(1), pp. 20-6.